Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410]

  • Topic prioritisation

NIHRIO BN - 25409-Ruxolitinib-for-Graft-Versus-Host-Disease-V1.0-NOV2023-NON-CONF.pdf (nihr.ac.uk)